Combined immunotherapy and radiation induce cellular and humoral immune responses to tumor-associated antigens and prolong survival of patients with advanced cancers.

Immunotherapy is effective in treating patients with a variety of cancers We developed and employed an immunotherapeutic protocol that combined intra-tumor injection autologous immature dendritic cells , standard care radiation to treat different advanced solid tumors. Pre post treatment peripheral blood mononuclear ( PBMC) were assayed for their capacity kill tumor cell lines had been established from PBMC obtained cytotoxic but not allogeneic lines. Cytotoxic activity increased as relative numbers CD8+-CD56+ dual positive lymphoid treatment. The line directed cytotoxicity was shown be mediated by both innate adaptive immune mechanisms. Cytotoxicity enhanced after co-culture lysates. Antibody mesothelin, associated antigen expressed tumors, serum samples lung cancer patients. These sera antibody cellular ADCC) mesothelin expressing SSurvival 96 treated on this over 3 year period followed 1000+ days significantly low burden lesion at <5 sites diameters < 3cm) (Km= <0.0001) regardless malignancy. findings support application combination immunotherapy the disease